AMEDISYS INC0000896262false00008962622025-04-172025-04-17

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): April 17, 2025
Commission File Number: 0-24260

image0.jpg
 
AMEDISYS, INC.
(Exact Name of Registrant as specified in its Charter) 
  
Delaware
11-3131700
(State or other jurisdiction of
incorporation or organization)
(I.R.S. Employer
Identification No.)
3854 American Way, Suite A, Baton Rouge, LA 70816
(Address of principal executive offices, including zip code)

(225) 292-2031 or (800) 467-2662
(Registrant’s telephone number, including area code) 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, par value $0.001 per shareAMEDThe NASDAQ Global Select Market
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
 





SECTION 1 — REGISTRANT'S BUSINESS AND OPERATIONS

ITEM 1.01. ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT
On April 17, 2025, Amedisys, Inc. ("we," "us," "our," or "the Company") entered into a Fourth Amendment to its Amended and Restated Credit Agreement, effective as of that date (the “Fourth Amendment”), by and among the Company and Amedisys Holding, L.L.C., a wholly-owned subsidiary of the Company, as the borrowers, certain subsidiaries of the Company that are party thereto as guarantors, Bank of America, N.A., as the administrative agent, swingline lender and letter of credit issuer, JPMorgan Chase Bank, N.A. as a lender and letter of credit issuer, and Citizens Bank, N.A., Fifth Third Bank, National Association, PNC Bank, National Association, Regions Bank, Capital One Bank, National Association, Wells Fargo Bank, National Association, Hancock Whitney Bank, and BOKF, NA DBA Bank of Texas, as lenders. The Fourth Amendment amends the Amended and Restated Credit Agreement, dated as of June 29, 2018, as amended by the First Amendment to the Amended and Restated Credit Agreement, dated as of February 4, 2019, as further amended by the Second Amendment to the Amended and Restated Credit Agreement, dated as of July 30, 2021, and as further amended by the Third Amendment to the Amended and Restated Credit Agreement, dated as of March 10, 2023 (the “Existing Credit Agreement”).
The Existing Credit Agreement provides for a senior secured credit facility in an aggregate principal amount of up to $1.0 billion, which includes a $550.0 million Revolving Credit Facility (the “Revolving Credit Facility”), and a term loan facility with a principal amount of up to $450.0 million (the “Term Loan Facility” and collectively with the Revolving Credit Facility, the “Credit Facility”).
Pursuant to the Fourth Amendment, the parties to the Existing Credit Agreement (i) extended the maturity date of the Credit Facility from July 30, 2026 to July 30, 2027; (ii) added certain provisions for “Outbound Investment Rules” that relate to the regulations administered and enforced by the United States Treasury Department under U.S. Executive Order 14105 of August 9, 2023, or any similar law or regulation; and (iii) made certain other amendments to the Existing Credit Agreement.
The foregoing description of the Fourth Amendment does not purport to be complete and is qualified in its entirety by reference to the Fourth Amendment filed as Exhibit 10.1 of this report and incorporated herein by reference.


SECTION 2 — FINANCIAL INFORMATION

ITEM 2.02. RESULTS OF OPERATIONS AND FINANCIAL CONDITION
On April 23, 2025, the Company issued a press release (the “Press Release”) announcing its financial results for the three-month period ended March 31, 2025. A copy of the Press Release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
The information presented in Item 2.02 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, unless we specifically state that the information is to be considered “filed” under the Exchange Act or specifically incorporate it by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act.
ITEM 2.03. CREATION OF A DIRECT FINANCIAL OBLIGATION OR AN OBLIGATION UNDER AN OFF-BALANCE SHEET ARRANGEMENT OF REGISTRANT
The information provided in Item 1.01 of this Current Report on Form 8-K is hereby incorporated into this Item 2.03 by reference.

SECTION 7 — REGULATION FD

ITEM 7.01. REGULATION FD DISCLOSURE
Item 2.02 of this Current Report on Form 8-K is incorporated herein by reference.
In addition, a copy of the Company's first quarter supplemental slides are attached to this report as Exhibit 99.2 and incorporated herein by reference.
The information included in this Current Report on Form 8-K under this Item 7.01 (including Exhibits 99.1 and 99.2 hereto) is being “furnished” and shall not be deemed to be “filed” for the purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of Section 18, nor shall it be incorporated by reference into a filing under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such filing. The information included in this Current Report on Form 8-K under



this Item 7.01 (including Exhibits 99.1 and 99.2 hereto) will not be deemed an admission as to the materiality of any information required to be disclosed solely to satisfy the requirements of Regulation FD.



SECTION 9 — FINANCIAL STATEMENTS AND EXHIBITS
ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS
(d) Exhibits.
10.1
99.1
99.2
104Cover Page Interactive Data File (embedded within the Inline XBRL document)




Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. 
AMEDISYS, INC.
(Registrant)

By:    /s/ Scott G. Ginn
    Scott G. Ginn
    Chief Operating Officer, Executive Vice President and Chief Financial Officer
    (Principal Financial Officer)

DATE: April 23, 2025



Exhibit 10.1

EXECUTION VERSION


FOURTH AMENDMENT TO AMENDED AND RESTATED CREDIT AGREEMENT

THIS FOURTH AMENDMENT TO AMENDED AND RESTATED CREDIT AGREEMENT (this “Agreement”), dated as of April 17, 2025 (the “Fourth Amendment Effective Date”), is entered into among AMEDISYS, INC., a Delaware corporation (the “Company”), AMEDISYS HOLDING, L.L.C., a Louisiana limited liability company (“Amedisys Holding”; Amedisys Holding, together with the Company, each a “Borrower” and collectively, the “Borrowers”), the Guarantors party hereto, the Lenders party hereto, Bank of America, N.A., as Administrative Agent, Swingline Lender and L/C Issuer, and the other L/C Issuers party hereto.

RECITALS

WHEREAS, the Borrowers, the Guarantors party thereto, the Lenders from time to time party thereto, Bank of America, N.A., as Administrative Agent, Swingline Lender and L/C Issuer, and the other L/C Issuers party thereto, have entered into that certain Amended and Restated Credit Agreement dated as of June 29, 2018 (as amended, modified, extended, restated, replaced, or supplemented from time to time, the “Credit Agreement”);

WHEREAS, the Borrowers have requested that the Credit Agreement be amended as set forth below, subject to the terms and conditions specified in this Agreement; and

WHEREAS, the Administrative Agent is authorized pursuant to clause (z) of the penultimate paragraph in Section 11.01 of the Credit Agreement to make Conforming Changes from time to time and, in reliance on such authorization, the Administrative Agent desires to amend the Credit Agreement to make certain Confirming Changes as set forth in the amendments to the definitions of “Term SOFR” and “U.S. Government Securities Business Day” in Section 2(b) below.

NOW, THEREFORE, in consideration of the premises and the mutual covenants contained herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:

1. Defined Terms.

Capitalized terms used herein and not otherwise defined herein shall have the meanings given to such terms in the Credit Agreement.

2. Amendments to Credit Agreement.

(a) The following definitions are added to Section 1.01 of the Credit Agreement in the appropriate alphabetical order:

Fourth Amendment Effective Date” means April 17, 2025.

Outbound Investment Rules” means the regulations administered and enforced, together with any related public guidance issued, by the United States Treasury Department under U.S. Executive Order 14105 of August 9, 2023, or any similar law or regulation; as of the Fourth Amendment Effective Date, and as codified at 31 C.F.R. § 850.101 et seq.

(b) The following definitions in Section 1.01 of the Credit Agreement are amended and restated in their entireties to read as follows:




Fee Letter” means the fee letter agreement, dated July 6, 2021, among the Borrowers, Bank of America and BofA Securities and/or the fee letter agreement, dated April 7, 2025, among the Borrowers and BofA Securities, as the context may require.

Revolving Facility Maturity Date” means July 30, 2027; provided, that, if such date is not a Business Day, the Revolving Facility Maturity Date shall be the next preceding Business Day.

Term Facility Maturity Date” means July 30, 2027; provided, that, if such date is not a Business Day, the Term Facility Maturity Date shall be the next preceding Business Day.

Term SOFR” means: (a) for any Interest Period with respect to a Term SOFR Loan, the rate per annum equal to the Term SOFR Screen Rate two U.S. Government Securities Business Days prior to the commencement of such Interest Period with a term equivalent to such Interest Period; provided, that, if the rate is not published prior to 11:00 a.m. on such determination date then Term SOFR means the Term SOFR Screen Rate on the first U.S. Government Securities Business Day immediately prior thereto; in each case, plus the SOFR Adjustment for such Interest Period; and (b) for any interest calculation with respect to a Base Rate Loan on any date, the rate per annum equal to the Term SOFR Screen Rate two U.S. Government Securities Business Days prior to such date with a term of one month commencing that day; provided, that, if the rate is not published prior to 11:00 a.m. on such determination date then Term SOFR means the Term SOFR Screen Rate on the first U.S. Government Securities Business Day immediately prior thereto, in each case, plus the SOFR Adjustment for such term; provided, that, if Term SOFR determined in accordance with either of the foregoing clause (a) or clause (b) of this definition would otherwise be less than zero, Term SOFR shall be deemed zero for purposes of this Agreement.

U.S. Government Securities Business Day” means any day except for (a) a Saturday, (b) a Sunday or (c) a day on which the Securities Industry and Financial Markets Association recommends that the fixed income departments of its members be closed for the entire day for
purposes of trading in United States government securities.

(c) In the definition of “Excluded Property” in Section 1.01 of the Credit Agreement, (i) the existing clause (j) is renumbered to be clause (k) and (ii) a new clause (j) is added to read as follows:

, (j) any property constituting margin stock (within the meaning of Regulation U issued by
the FRB)

(d) The table in Section 2.07(d) of the Credit Agreement is amended and restated in its entirety to read as follows:

Payment Date
Principal Amortization Payment (% of Outstanding Amount of Term Loans as of the Second Amendment Effective Date)
December, 2021
0.625%
March, 2022
0.625%
June, 2022
0.625%
September, 2022
0.625%
December, 2022
0.625%
March, 2023
0.625%
June, 2023
0.625%
September, 2023
0.625%
December, 2023
1.250%
March, 2024
1.250%



June, 2024
1.250%
September, 2024
1.250%
December, 2024
1.250%
March, 2025
1.250%
June, 2025
1.250%
September, 2025
1.250%
December, 2025
1.250%
March, 2026
1.250%
June, 2026
1.250%
September, 2026
1.250%
December, 2026
1.250%
March, 2027
1.250%
June, 2027
1.250%
Term Facility Maturity Date
Outstanding Principal Balance
of Term Loans
(e) A new Section 5.26 is added to Article V of the Credit Agreement to read as follows:

5.26 Outbound Investment Rules.

Neither the Company nor any of its Subsidiaries is a “covered foreign person” as that term is used in the Outbound Investment Rules. Neither the Company nor any of its Subsidiaries currently engages, or has any present intention to engage in the future, directly or indirectly, in (i) a “covered activity” or a “covered transaction”, as each such term is defined in the Outbound Investment Rules, (ii) any activity or transaction that would constitute a “covered activity” or a “covered transaction”, as each such term is defined in the Outbound Investment Rules, or (iii) any other activity that would cause the Administrative Agent or the Lenders to be in violation of the Outbound Investment Rules or cause the Administrative Agent or the Lenders to be legally prohibited by the Outbound Investment Rules from performing under this Agreement.

(f) A new Section 7.20 is added to Article VII of the Credit Agreement to read as follows:

7.20 Outbound Investment Rules.

(a) Be or become a “covered foreign person”, as that term is defined in the
Outbound Investment Rules, or (b) engage, directly or indirectly, in (i) a “covered activity” or a “covered transaction”, as each such term is defined in the Outbound Investment Rules, (ii) any activity or transaction that would constitute a “covered activity” or a “covered transaction”, as each such term is defined in the Outbound Investment Rules, or (iii) any other activity that would cause the Administrative Agent or the Lenders to be in violation of the Outbound Investment Rules or cause the Administrative Agent or the Lenders to be legally prohibited by the Outbound Investment Rules from performing under this Agreement.

(g) A new clause (e) is added in Section 11.07 of the Credit Agreement to read as follows:

(e) Disclosures Regarding Suspected Violations of Laws, etc. For the avoidance of doubt, nothing herein prohibits any individual from communicating or disclosing information regarding suspected violations of laws, rules, or regulations to a governmental, regulatory, or self-regulatory authority without any notification to any person.




3. Condition Precedent. This Agreement shall become effective upon satisfaction of the following conditions precedent:

(a) receipt by the Administrative Agent of counterparts of this Agreement, properly executed by a Responsible Officer of each Loan Party, each Lender, the Swingline Lender, each L/C Issuer and the Administrative Agent;

(b) receipt by the Administrative Agent of the following, in form and substance satisfactory to the Administrative Agent and its legal counsel: (i) copies of the Organization Documents of the Borrowers certified to be true and complete as of a recent date by the appropriate Governmental Authority of the jurisdiction of its organization or incorporation, where applicable, and certified by a secretary or assistant secretary of such Borrower to be true and correct as of the Fourth Amendment Effective Date (provided, that, with respect to any such Organization Documents that have not been amended, modified or terminated (other than any modification resulting solely from a change in the registered agent for such Borrower) since the date previously delivered to the Administrative Agent, such Borrower may certify that such Organization Documents have not been amended, modified or terminated (other than any modification resulting solely from a change in the registered agent for such Borrower) since such date and remain in full force and effect, and remain true and complete (other than any modification resulting solely from a change in the registered agent for such Borrower), in the form delivered to the Administrative Agent on such date); (ii) such certificates of resolutions or other action, incumbency certificates and/or other certificates of Responsible Officers of each Borrower as the Administrative Agent may require evidencing the identity, authority and capacity of each Responsible Officer thereof authorized to act as a Responsible Officer in connection with this Agreement and the other Loan Documents to which such Borrower is a party; and (iii) such documents and certifications as the Administrative Agent may reasonably require to evidence that each Borrower is duly organized or formed, and is validly existing, in good standing and qualified to engage in business in its jurisdiction of organization or incorporation;

(c) receipt by the Administrative Agent of an opinion or opinions of counsel for the Borrowers, dated the Fourth Amendment Effective Date and addressed to the Administrative Agent and the Lenders, in form and substance reasonably acceptable to the Administrative Agent;

(d) receipt by the Administrative Agent of any fees owing to the Administrative Agent, the Arrangers and the Lenders that are required to be paid on or before the Fourth Amendment Effective Date; and

(e) (i) the Administrative Agent and the Lenders shall have completed a due diligence investigation of the Loan Parties and their Subsidiaries in scope, and with results, satisfactory to the Administrative Agent and the Lenders, including with respect to OFAC, the Foreign Corrupt Practices Act and “know your customer” due diligence, (ii) upon the request of any Lender made at least ten (10) days prior to the Fourth Amendment Effective Date, the Borrowers shall have provided to such Lender (and such Lender shall be reasonably satisfied with) the documentation and other information so requested in connection with applicable “know your customer” and anti-money-laundering rules and regulations, including the PATRIOT Act, in each case at least five (5) days prior to the Fourth Amendment Effective Date, and (iii) at least five (5) days prior to the Fourth Amendment Effective Date, if any Borrower qualifies as a “legal entity customer” under the Beneficial Ownership Regulation, such Borrower shall deliver, to each Lender that so requests, a Beneficial Ownership Certification in relation to such Borrower.

For purposes of determining compliance with the conditions specified in this Section 3, each Lender that has signed this Agreement shall be deemed to have consented to, approved or accepted or to be satisfied
with, each document or other matter required thereunder to be consented to or approved by or acceptable
or satisfactory to a Lender unless the Administrative Agent shall have received notice from such Lender prior to the proposed Fourth Amendment Effective Date specifying its objection thereto.

4. Payment of Expenses. The Loan Parties agree to reimburse the Administrative Agent for all reasonable fees, charges, and disbursements of the Administrative Agent in connection with the preparation, execution, and delivery of this Agreement, including all reasonable fees, charges, and disbursements of counsel to the Administrative Agent (paid directly to such counsel if requested by the Administrative Agent).





5. Miscellaneous.

(a) The Loan Documents (as expressly amended and modified by this Agreement) and the obligations of the Loan Parties thereunder are hereby ratified and confirmed and shall remain in full force and effect according to their terms. This Agreement shall constitute a Loan Document.

(b) Each Loan Party (i) agrees that the Collateral Documents continue to be in full force and effect and are not impaired or adversely affected in any manner whatsoever, (ii) confirms its grant of security interests pursuant to the Collateral Documents to which it is a party as Collateral for the Secured Obligations, and (iii) acknowledges that all Liens granted (or purported to be granted) pursuant to the Collateral Documents remain and continue in full force and effect in respect of, and to secure, the Secured Obligations.

(c) Each Guarantor (i) acknowledges and consents to all of the terms and conditions of this Agreement, (ii) affirms all of its obligations under the Loan Documents, and (iii) agrees that this Agreement and all documents executed in connection herewith do not operate to reduce or discharge its obligations under the Loan Documents.

(d) Each Loan Party hereby represents and warrants as follows: (i) such Loan Party has taken
all necessary corporate, limited liability or other organizational action to authorize the execution, delivery and performance of this Agreement; (ii) this Agreement has been duly executed and delivered by such Loan Party and constitutes the legal, valid and binding obligation of such Loan Party, enforceable against such Loan Party in accordance with its terms, except as enforceability may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or similar laws affecting the enforcement of creditors’ rights generally and by general equitable principles and/or principles of good faith and fair dealing (whether enforcement is sought by proceedings in equity or at law); (iii) no approval, consent, exemption, authorization or other action by, or notice to, or filing with, any Governmental Authority or any other Person is necessary or required in connection with the execution, delivery or performance by, or enforcement against, such Loan Party of this Agreement; and (iv) after giving effect to the transactions contemplated by this Agreement to occur on the Fourth Amendment Effective Date, (A) the representations and warranties of the Company and each other Loan Party contained in Article II and Article V of the Credit Agreement or in any other Loan Document, or which are contained in any document furnished at any time under or in connection therewith, are true and correct in all material respects (and in all respects if any such representation and warranty is already qualified by materiality or reference to Material Adverse Effect) on and as of the Fourth Amendment Effective Date, except to the extent such representations and warranties specifically refer to an earlier date, in which case they shall be true and correct in all material respects (and in all respects if any such representation or warranty is already qualified by materiality or reference to Material Adverse Effect) as of such earlier date, and except that for purposes of this Section 5(d)(iv)(A), the representations and warranties contained in subsections (a) and (b) of Section 5.05 of the Credit Agreement shall be deemed to refer to the most recent statements furnished pursuant to clauses (a) and (b), respectively, of Section 6.01 of the Credit Agreement, and (B) no Default or Event of Default has occurred and is continuing.

(e) Subject to Section 11.18 of the Credit Agreement, this Agreement may be in the form of an Electronic Record and may be executed using Electronic Signatures (including facsimile and .pdf) and shall be considered an original, and shall have the same legal effect, validity and enforceability as a paper record. This Agreement may be executed in as many counterparts as necessary or convenient, including both paper and electronic counterparts, but all such counterparts are one and the same Agreement. The authorization under this Section 5(e) may include use or acceptance by the Administrative Agent, any L/C Issuer and each Lender of a manually signed paper copy of this Agreement which has been converted into electronic form (such as scanned into .pdf format), or an electronically signed copy of this Agreement converted into another format, for transmission, delivery and/or retention.

(f) If any provision of this Agreement is held to be illegal, invalid or unenforceable, (i) the legality, validity and enforceability of the remaining provisions of this Agreement shall not be affected or impaired thereby and (ii) the parties shall endeavor in good faith negotiations to replace the illegal, invalid or unenforceable provisions with valid provisions the economic effect of which comes as close as possible to that of the illegal,



invalid or unenforceable provisions. The invalidity of a provision in a particular jurisdiction shall not invalidate or render unenforceable such provision in any other jurisdiction.

(g) THIS AGREEMENT AND ANY CLAIMS, CONTROVERSY, DISPUTE OR CAUSE OF ACTION (WHETHER IN CONTRACT OR TORT OR OTHERWISE) BASED UPON, ARISING OUT OF OR RELATING TO THIS AGREEMENT AND THE TRANSACTIONS CONTEMPLATED HEREBY SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK.

(h) The terms of Sections 11.14 and 11.15 of the Credit Agreement with respect to submission to jurisdiction, waiver of venue and waiver of jury trial are incorporated herein by reference, mutatis mutandis, and the parties hereto agree to such terms.




[remainder of page intentionally left blank]











































Each of the parties hereto has caused a counterpart of this Agreement to be duly executed and delivered as of the date first above written.

BORROWERS:                
AMEDISYS, INC.,
a Delaware corporation
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Chief Financial Officer and Executive Vice President

AMEDISYS HOLDING, L.L.C.,
a Louisiana limited liability company
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer

GUARANTORS:            
ACCUMED HEALTH SERVICES, L.L.C.,
a Texas limited liability company
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer

ACCUMED HOME HEALTH OF GEORGIA, L.L.C.,
a Georgia limited liability company
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer

ADVENTA HOSPICE, L.L.C.,
a Florida limited liability company
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer

ALBERT GALLATIN HOME CARE AND HOSPICE SERVICES, LLC,
a Delaware limited liability company
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer

AMEDISYS ALABAMA, L.L.C.,
an Alabama limited liability company
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer

AMEDISYS ARIZONA, L.L.C.,
an Arizona limited liability company
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer





AMEDISYS ARKANSAS, LLC,
an Arkansas limited liability company
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer

AMEDISYS BA, LLC,
a Delaware limited liability company
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer

AMEDISYS DELAWARE, L.L.C.,
a Delaware limited liability company
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer

AMEDISYS FLORIDA, L.L.C.,
a Florida limited liability company
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer

AMEDISYS GEORGIA, L.L.C.,
a Georgia limited liability company
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer

AMEDISYS HEALTH CARE WEST, L.L.C.,
a Delaware limited liability company
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer

AMEDISYS HOME HEALTH OF ALABAMA, L.L.C.,
an Alabama limited liability company
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer

AMEDISYS HOME HEALTH OF SOUTH CAROLINA, L.L.C.,
a South Carolina limited liability company
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer

AMEDISYS HOME HEALTH OF VIRGINIA, L.L.C.,
a Virginia limited liability company
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer




AMEDISYS HOSPICE, L.L.C.,
a Louisiana limited liability company
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer

AMEDISYS IDAHO, L.L.C.,
an Idaho limited liability company
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer

AMEDISYS ILLINOIS, L.L.C.,
an Illinois limited liability company
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer

AMEDISYS INDIANA, L.L.C.,
an Indiana limited liability company
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer

AMEDISYS KANSAS, L.L.C.,
a Kansas limited liability company
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer

AMEDISYS LA ACQUISITIONS, L.L.C.,
a Louisiana limited liability company
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer

AMEDISYS LOUISIANA, L.L.C.,
a Louisiana limited liability company
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer

AMEDISYS MAINE, P.L.L.C.,
a Maine professional limited liability company
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer

AMEDISYS MARYLAND, L.L.C.,
a Maryland limited liability company
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer




AMEDISYS MISSISSIPPI, L.L.C.,
a Mississippi limited liability company
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer

AMEDISYS MISSOURI, L.L.C.,
a Missouri limited liability company
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer

AMEDISYS NEW HAMPSHIRE, L.L.C.,
a New Hampshire limited liability company
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer

AMEDISYS NEW JERSEY, L.L.C.,
a New Jersey limited liability company
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer

AMEDISYS NORTH CAROLINA, L.L.C.,
a North Carolina limited liability company
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer

AMEDISYS NORTHWEST, L.L.C.,
a Georgia limited liability company
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer

AMEDISYS OHIO, L.L.C.,
an Ohio limited liability company
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer

AMEDISYS OKLAHOMA, L.L.C.,
an Oklahoma limited liability company
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer

AMEDISYS OREGON, L.L.C.,
an Oregon limited liability company
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer





AMEDISYS PENNSYLVANIA, L.L.C.,
a Pennsylvania limited liability company
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer

AMEDISYS PERSONAL CARE, LLC,
a Delaware limited liability company
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer

AMEDISYS RHODE ISLAND, L.L.C.,
a Rhode Island limited liability company
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer

AMEDISYS SC, L.L.C.,
a South Carolina limited liability company
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer

AMEDISYS SP-IN, L.L.C.,
an Indiana limited liability company
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer

AMEDISYS SP-KY, L.L.C.,
a Kentucky limited liability company
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer

AMEDISYS SP-OH, L.L.C.,
an Ohio limited liability company
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer

AMEDISYS SP-TN, L.L.C.,
a Tennessee limited liability company
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer

AMEDISYS TENNESSEE, L.L.C.,
a Tennessee limited liability company
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer





AMEDISYS TEXAS, L.L.C.,
a Texas limited liability company
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer

AMEDISYS TLC ACQUISITION, L.L.C.,
a Louisiana limited liability company
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer

AMEDISYS WASHINGTON, L.L.C.,
a Washington limited liability company
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer

AMEDISYS WEST VIRGINIA, L.L.C.,
a West Virginia limited liability company
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer

AMEDISYS WISCONSIN, L.L.C.,
a Wisconsin limited liability company
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer

ANGEL WATCH HOME CARE, L.L.C.,
a Florida limited liability company
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer

AVENIR VENTURES, L.L.C.,
a Louisiana limited liability company
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer

BEACON HOSPICE, L.L.C.,
a Delaware limited liability company
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer

COMPREHENSIVE HOME HEALTHCARE SERVICES, L.L.C.,
a Tennessee limited liability company
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer





EMERALD CARE, L.L.C.,
a North Carolina limited liability company
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer

FAMILY HOME HEALTH CARE, L.L.C.,
a Kentucky limited liability company
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer

HI-TECH CARE, INC.,
a Florida corporation
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer

HHC, L.L.C.,
a Tennessee limited liability company
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer

HOME HEALTH OF ALEXANDRIA, L.L.C.,
a Louisiana limited liability company
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer

HORIZONS HOSPICE CARE, L.L.C.,
an Alabama limited liability company
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer

HOUSECALL HOME HEALTH, L.L.C.,
a Tennessee limited liability company
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer

INFINITY HOME CARE, L.L.C.,
a Florida limited liability company
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer

INFINITY HOME CARE ACQUISITION CORP.,
a Florida corporation
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer





INFINITY HOME CARE OF JACKSONVILLE, LLC,
a Florida limited liability company
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer

INFINITY HOME CARE OF LAKELAND, LLC,
a Florida limited liability company
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer

INFINITY HOME CARE OF OCALA, LLC,
a Florida limited liability company
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer

INFINITY HOME CARE OF PORT CHARLOTTE, LLC,
a Florida limited liability company
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer

INFINITY HOMECARE OF DISTRICT 9, LLC,
a Florida limited liability company
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer

NINE PALMS 2, LLC,
a Mississippi limited liability company
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer

NINE PALMS 1, L.L.C.,
a Virginia limited liability company
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer

TENDER LOVING CARE HEALTH CARE SERVICES
INTERNATIONAL, LLC,
a Delaware limited liability company
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer

TENDER LOVING CARE HEALTH CARE SERVICES OF ERIE                         
NIAGARA, LLC,
a New York limited liability company
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer




TENDER LOVING CARE HEALTH CARE SERVICES OF GEORGIA,
LLC,
a Delaware limited liability company
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer

TENDER LOVING CARE HEALTH CARE SERVICES OF NASSAU
SUFFOLK, LLC,
a New York limited liability company
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer

TENDER LOVING CARE HEALTH CARE SERVICES OF NEW
ENGLAND, LLC,
a Delaware limited liability company
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer

TENDER LOVING CARE HEALTH CARE SERVICES OF WEST
VIRGINIA, LLC,
a Delaware limited liability company
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer

TENDER LOVING CARE HEALTH CARE SERVICES SOUTHEAST,
LLC,
a Delaware limited liability company
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer

TENDER LOVING CARE HEALTH CARE SERVICES WESTERN,
LLC,
a Delaware limited liability company
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer

TLC HEALTH CARE SERVICES, L.L.C.,
a Delaware limited liability company
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer

TLC HOLDINGS I, L.L.C.,
a Delaware limited liability company
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer




HOSPICE PREFERRED CHOICE, INC.,
a Delaware corporation
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer

HOSPICE OF EASTERN CAROLINA, INC.,
a North Carolina corporation
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer

HOMECARE PREFERRED CHOICE, INC.,
a Delaware corporation
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer

ASERACARE HOSPICE – TENNESSEE, LLC,
a Delaware limited liability company
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer

ASERACARE HOSPICE – SENATOBIA, LLC,
a Delaware limited liability company
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer

ASERACARE HOSPICE – RUSSELLVILLE, LLC,
a Delaware limited liability company
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer

ASERACARE HOSPICE – NEW HORIZONS, LLC,
a Delaware limited liability company
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer

ASERACARE HOSPICE – MONROEVILLE, LLC,
a Delaware limited liability company
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer

ASERACARE HOSPICE – JACKSON, LLC,
a Delaware limited liability company
BBy: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer





ASERACARE HOSPICE – HAMILTON, LLC,
a Delaware limited liability company
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer

ASERACARE HOSPICE – DEMOPOLIS, LLC,
a Delaware limited liability company
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer

COMPASSIONATE CARE HOSPICE OF DELAWARE, L.L.C.,
a Delaware limited liability company
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer

COMPASSIONATE CARE HOSPICE OF THE DELMAR PENINSULA,                         
LLC,
a Delaware limited liability company
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer

COMPASSIONATE CARE HOSPICE GROUP, INC.,
a Florida corporation
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer

COMPASSIONATE CARE HOSPICE OF CENTRAL FLORIDA,
INC.,
a Florida corporation
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer

COMPASSIONATE CARE HOSPICE OF MIAMI DADE AND
THE FLORIDA KEYS, INC.,
a Florida corporation
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer

COMPASSIONATE CARE HOSPICE OF LAKE AND SUMTER,
INC.,
a Florida corporation
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer






COMPASSIONATE CARE HOSPICE OF CENTRAL GEORGIA, LLC,
a Georgia limited liability company
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer

COMPASSIONATE CARE HOSPICE OF NORTHERN
GEORGIA, LLC,
a Georgia limited liability company
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer

COMPASSIONATE CARE HOSPICE OF SAVANNAH, LLC,
a Georgia limited liability company
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer

COMPASSIONATE CARE HOSPICE OF ILLINOIS, LLC,
an Illinois limited liability company
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer

COMPASSIONATE CARE HOSPICE OF KANSAS CITY, LLC,
a Kansas limited liability company
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer

COMPASSIONATE CARE HOSPICE OF CENTRAL
LOUISIANA, LLC,
a Louisiana limited liability company
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer

COMPASSIONATE CARE HOSPICE OF MASSACHUSETTS, LLC,
a Massachusetts limited liability company
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer

COMPASSIONATE CARE HOSPICE OF SOUTHEASTERN
MASSACHUSETTS, LLC,
a Massachusetts limited liability company
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer







COMPASSIONATE CARE HOSPICE OF MICHIGAN, LLC,
a Michigan limited liability company
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer

COMPASSIONATE CARE HOSPICE OF MINNESOTA, LLC,
a Minnesota limited liability company
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer

COMPASSIONATE CARE HOSPICE OF SOUTHERN
MISSISSIPPI, LLC,
a Mississippi limited liability company
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer

PATHWAYS TO COMPASSION, LLC,
a Nebraska limited liability company
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer

COMPASSIONATE CARE HOSPICE OF NEW HAMPSHIRE,
LLC,
a New Hampshire limited liability company
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer

COMPASSIONATE CARE HOSPICE OF CLIFTON, L.L.C.,
a New Jersey limited liability company
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer

COMPASSIONATE CARE HOSPICE OF MARLTON, L.L.C.,
a New Jersey limited liability company
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer

COMPASSIONATE CARE HOSPICE OF NORTHERN NEW
JERSEY, LLC,
a New Jersey limited liability company
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer







PATHWAYS TO COMPASSION, LLC,
a New Jersey limited liability company
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer

COMPASSIONATE CARE HOSPICE OF OHIO, LLC,
an Ohio limited liability company
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer

COMPASSIONATE CARE HOSPICE, L.L.C.,
a Pennsylvania limited liability company
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer

COMPASSIONATE CARE HOSPICE OF GWYNEDD, L.L.C.,
a Pennsylvania limited liability company
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer

COMPASSIONATE CARE HOSPICE OF NORTHWESTERN                     
PENNSYLVANIA, LLC,
a Pennsylvania limited liability company
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer

COMPASSIONATE CARE HOSPICE OF PITTSBURGH, LLC,
a Pennsylvania limited liability company
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer

COMPASSIONATE CARE HOSPICE OF SOUTH CAROLINA,
LLC,
a South Carolina limited liability company
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer

COMPASSIONATE CARE HOSPICE OF THE MIDWEST, LLC,
a South Dakota limited liability company
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer








COMPASSIONATE CARE HOSPICE OF BRYAN TEXAS, LLC,
a Texas limited liability company
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer

COMPASSIONATE CARE HOSPICE OF CENTRAL TEXAS,
LLC,
a Texas limited liability company
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer

COMPASSIONATE CARE HOSPICE OF HOUSTON, LLC,
a Texas limited liability company
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer

COMPASSIONATE CARE HOSPICE OF NORTH TEXAS, LLC,
a Texas limited liability company
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer

COMPASSIONATE CARE HOSPICE OF SOUTHEASTERN
TEXAS, LLC,
a Texas limited liability company
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer

COMPASSIONATE CARE HOSPICE OF THE CHESAPEAKE BAY,
LLC,
a Virginia limited liability company
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer

COMPASSIONATE CARE HOSPICE OF WISCONSIN, LLC,
a Wisconsin limited liability company
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer

ASANA HOSPICE CLEVELAND, LLC,
a Delaware limited liability company
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer







ASANA PALLIATIVE CLEVELAND, LLC,
a Delaware limited liability company
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer

BEAUFORT HOME HEALTH PARTNERS, L.L.C.,
a Delaware limited liability company
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer

AMEDISYS HOME HEALTH OF NEBRASKA, L.L.C.,
a Nebraska limited liability company
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer

HOSPICE HOLDINGS DFW, LLC,
a Texas limited liability company
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer

HOSPICE HOLDINGS HARRISBURG, LLC,
a Pennsylvania limited liability company
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer

MISSOURI HOSPICE HOLDINGS, LLC,
a Missouri limited liability company
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer

OHIO HOSPICE HOLDINGS, LLC,
a Delaware limited liability company
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer

PENNSYLVANIA HOSPICE HOLDINGS, LLC,
a Pennsylvania limited liability company
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer

TAYLOR HOSPICE HOLDINGS, LLC,
a Pennsylvania limited liability company
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer







TEXAS HOSPICE HOLDINGS, LLC,
a Delaware limited liability company
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer

WT HOSPICE HOLDINGS, LLC,
a Pennsylvania limited liability company
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer

TUCSON HOME HEALTH, LLC,
a Delaware limited liability company
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer

CONTESSA HEALTH, INC.,
a Delaware corporation
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer

CONTESSA HEALTH HOLDING COMPANY, LLC,
a Delaware limited liability company
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer

CONTESSA HEALTH MANAGEMENT, LLC,
a Delaware limited liability company
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer

CONTRADO CLAIM, LLC,
a Delaware limited liability company
By: /s/Scott G. Ginn
Name: Scott G. Ginn
Title: Vice-President and Treasurer

ADMINISTRATIVE AGENT:     
BANK OF AMERICA, N.A.,
as Administrative Agent
By: /s/Carolen Alfonso
Name: Carolen Alfonso
Title: Vice President






LENDERS:     
BANK OF AMERICA, N.A.,
as Lender, L/C Issuer and Swingline Lender
By: /s/H. Hope Walker
Name: H. Hope Walker
Title: Senior Vice President

JPMORGAN CHASE BANK, N.A.,
as a Lender and L/C Issuer
By: /s/Helen D. Davis
Name: Helen D. Davis
Title: Executive Director

CITIZENS BANK, N.A.,
as a Lender
By: /s/Doug Cornett
Name: Doug Cornett
Title: Managing Director

FIFTH THIRD BANK, NATIONAL ASSOCIATION,
as a Lender
By: /s/John McChesney
Name: John McChesney
Title: Executive Director

PNC BANK, NATIONAL ASSOCIATION,
as a Lender
By: /s/Kristin Olson
Name: Kristin E. Olson
Title: Senior Vice President

REGIONS BANK,
as a Lender
By: /s/Allen Riley
Name: Allen Riley
Title: Director

CAPITAL ONE BANK, NATIONAL ASSOCIATION,
as a Lender
By: /s/Davin Engelson
Name: Davin Engelson
Title: Duly Authorized Signatory

WELLS FARGO BANK, NATIONAL ASSOCIATION,
as Lender
By: /s/C. Eugene Stunson Jr.
Name: Eugene Stunson
Title: Executive Director

HANCOCK WHITNEY BANK,
as a Lender
By: /s/David Bertani
Name: David Bertani
Title: Director, Sponsor Finance/Healthcare Banking





BOKF, NA DBA BANK OF TEXAS,
as a Lender
By: /s/Santiago Acuna
Name: Santiago Acuna
Title: Senior Vice President



Exhibit 99.1
draftof8k050418image1a.gif
            
AMEDISYS REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS

BATON ROUGE, Louisiana (April 23, 2025) — Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three-month period ended March 31, 2025.

Three-Month Periods Ended March 31, 2025 and 2024

Net service revenue increased $23.4 million to $594.8 million compared to $571.4 million in 2024.
Net income attributable to Amedisys, Inc. of $61.0 million, which is inclusive of merger-related expenses totaling $16.8 million ($16.6 million, net of tax) and a $48.1 million gain on an equity method investment ($35.6 million, net of tax), compared to net income attributable to Amedisys, Inc. of $14.4 million, which is inclusive of merger-related expenses totaling $20.7 million ($19.8 million, net of tax) in 2024.
Net income attributable to Amedisys, Inc. per diluted share of $1.84 compared to $0.44 in 2024.

Adjusted Quarterly Results*

Adjusted EBITDA of $68.8 million compared to $59.9 million in 2024.
Adjusted net income attributable to Amedisys, Inc. of $41.6 million compared to $33.9 million in 2024.
Adjusted net income attributable to Amedisys, Inc. per diluted share of $1.25 compared to $1.03 in 2024.



* See pages 7 - 8 for the definition and reconciliations of non-GAAP financial measures to GAAP measures.
The supplemental slides provided in connection with the first quarter 2025 earnings release can be found on the Investor Relations page of our website. In light of the pending merger of the Company with UnitedHealth Group Incorporated, Amedisys will not conduct a quarterly earnings call to discuss the first quarter results.
Non-GAAP Financial Measures
This press release includes reconciliations of the most comparable financial measures calculated and presented in accordance with accounting principles generally accepted in the U.S. (“GAAP”) to non-GAAP financial measures. The non-GAAP financial measures as defined under SEC rules are as follows: (1) adjusted EBITDA, defined as net income attributable to Amedisys, Inc. before net interest expense, provision for income taxes and depreciation and amortization, excluding certain items; (2) adjusted net income attributable to Amedisys, Inc., defined as net income attributable to Amedisys, Inc. calculated in accordance with GAAP excluding certain items; and (3) adjusted net income attributable to Amedisys, Inc. per diluted share, defined as net income attributable to Amedisys, Inc. common stockholders per diluted share calculated in accordance with GAAP excluding certain items. Certain items include merger-related expenses, unusual or non-recurring expenses and certain non-operational items. Management believes that these non-GAAP financial measures, when reviewed in conjunction with GAAP financial measures, are useful gauges of our current performance and are also included in internal management reporting. These non-GAAP financial measures should be considered in addition to, and not more meaningful than or as an alternative to, the GAAP financial measures presented in this earnings release and the company’s financial statements. Non-GAAP measures as presented herein may not be comparable to similarly titled measures reported by other companies since not all companies calculate these non-GAAP measures consistently.
1


Additional Information
Amedisys, Inc. (the “Company”) is a leading healthcare services company, delivering personalized home health, hospice and high acuity care services in the home. Amedisys is focused on delivering the care that is best for our patients, whether that is home-based recovery and rehabilitation after an operation or injury, care focused on empowering our patients to manage a chronic disease, hospice care at the end of life or in-patient hospital, palliative and skilled nursing facility ("SNF") care in their homes. More than 3,300 hospitals and 114,000 physicians nationwide have chosen Amedisys as a partner in post-acute care. Founded in 1982, headquartered in Baton Rouge, LA with an executive office in Nashville, TN, Amedisys is a publicly held company. With approximately 19,000 employees in 519 care centers within 38 states and the District of Columbia, Amedisys is dedicated to delivering the highest quality of care to the doorsteps of more than 499,000 patients every year. For more information about the Company, please visit: www.amedisys.com.
We use our website as a channel of distribution for important company information. Important information, including press releases, investor presentations and financial information regarding our company, is routinely posted on and accessible on the Investor Relations subpage of our website, which is accessible by clicking on the tab labeled “Investors” on our website home page. Visitors to our website can also register to receive automatic e-mail and other notifications alerting them when new information is made available on the Investor Relations subpage of our website.
Forward-Looking Statements
When included in this press release, words like “believes,” “belief,” “expects,” “strategy,” “plans,” “anticipates,” “intends,” “projects,” “estimates,” “may,” “might,” “will,” “could,” “would,” “should” and similar expressions are intended to identify forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve a variety of risks and uncertainties that could cause actual results to differ materially from those described therein. These risks and uncertainties include, but are not limited to, the following: disruption from the proposed merger with UnitedHealth Group with patient, payor, provider, referral source, supplier or management and employee relationships; the occurrence of any event, change or other circumstances that could give rise to the termination of the merger agreement with UnitedHealth Group or the inability to complete the proposed transaction on the anticipated terms or by the end of the waiver period under the merger agreement; the risk that necessary regulatory approvals for the proposed merger with UnitedHealth Group are delayed, are not obtained or are obtained subject to conditions that are not anticipated; the failure of the conditions to the proposed merger to be satisfied; the costs related to the proposed transaction; the diversion of management time on merger-related issues; the risk that termination fees may be payable by the Company in the event that the merger agreement is terminated under certain circumstances; reputational risk related to the proposed merger; the risk of litigation or regulatory action related to the proposed merger, including among other things, the action by the Department of Justice to block the merger; changes in Medicare and other medical payment levels; changes in payments and covered services by federal and state governments; future cost containment initiatives undertaken by third-party payors; changes in the episodic versus non-episodic mix of our payors, the case mix of our patients and payment methodologies; staffing shortages driven by the competitive labor market; our ability to attract and retain qualified personnel; competition in the healthcare industry; our ability to maintain or establish new patient referral sources; changes in or our failure to comply with existing federal and state laws or regulations or the inability to comply with new government regulations on a timely basis; changes in estimates and judgments associated with critical accounting policies; our ability to consistently provide high-quality care; our ability to keep our patients and employees safe; our access to financing; our ability to meet debt service requirements and comply with covenants in debt agreements; business disruptions due to natural or man-made disasters, climate change or acts of terrorism, widespread protests or civil unrest; our ability to open care centers, acquire additional care centers and integrate and operate these care centers effectively; our ability to realize the anticipated benefits of acquisitions, investments and joint ventures; our ability to integrate, manage and keep our information systems secure; the impact of inflation; the impact of new or increased tariffs; uncertainty around, and disruption from, new and emerging technologies, including the adoption and utilization of artificial intelligence ("AI") and generative AI and changes in laws or developments with respect to any litigation relating to the Company, including various other matters, many of which are beyond our control.
Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on any forward-looking statement as a prediction of future events. We expressly disclaim any obligation or undertaking, and we do not intend to release publicly any updates or changes in our expectations concerning the forward-looking statements or any changes in events, conditions or circumstances upon which any forward-looking statement may be based, except as required by law.


Contact:    Investor Contact:                Media Contact:            
Amedisys, Inc.                    Amedisys, Inc.
        Nick Muscato                    Kendra Kimmons
        Chief Strategy Officer             Vice President, Marketing & Communications
    (615) 928- 5452                    (225) 299-3720
        IR@amedisys.com             kendra.kimmons@amedisys.com    
2


AMEDISYS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED INCOME STATEMENTS
(Amounts in thousands, except per share data)

 For the Three-Month 
Periods Ended March 31,
 20252024
Net service revenue$594,781 $571,414 
Operating expenses:
Cost of service, inclusive of depreciation334,050 321,537 
General and administrative expenses:
Salaries and benefits131,968 127,946 
Non-cash compensation6,223 7,433 
Merger-related expenses16,769 20,667 
Depreciation and amortization4,447 4,271 
Other57,965 57,941 
Total operating expenses551,422 539,795 
Operating income43,359 31,619 
Other income (expense):
Interest income2,873 1,727 
Interest expense(6,422)(8,119)
Equity in earnings from equity method investments1,794 910 
Gain on equity method investment48,093 — 
Miscellaneous, net1,508 1,090 
Total other income (expense), net47,846 (4,392)
Income before income taxes91,205 27,227 
Income tax expense(29,384)(12,633)
Net income61,821 14,594 
Net income attributable to noncontrolling interests(809)(194)
Net income attributable to Amedisys, Inc.$61,012 $14,400 
Basic earnings per common share:
Net income attributable to Amedisys, Inc. common stockholders$1.86 $0.44 
Weighted average shares outstanding32,793 32,670 
Diluted earnings per common share:
Net income attributable to Amedisys, Inc. common stockholders$1.84 $0.44 
Weighted average shares outstanding33,218 32,979 

3


AMEDISYS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(Amounts in thousands, except share data)
March 31, 2025December 31, 2024
ASSETS
Current assets:
Cash and cash equivalents$284,881 $303,242 
Patient accounts receivable319,639 296,075 
Prepaid expenses17,410 13,072 
Other current assets12,034 19,694 
Total current assets633,964 632,083 
Property and equipment, net of accumulated depreciation of $103,758 and $100,890
40,186 42,108 
Operating lease right of use assets80,905 81,500 
Goodwill1,213,888 1,213,888 
Intangible assets, net of accumulated amortization of $19,949 and $18,787
80,199 81,155 
Other assets135,432 87,980 
Total assets$2,184,574 $2,138,714 
LIABILITIES AND EQUITY
Current liabilities:
Accounts payable$28,705 $39,956 
Payroll and employee benefits131,722 151,995 
Accrued expenses162,180 152,564 
Termination fee paid by UnitedHealth Group106,000 106,000 
Current portion of long-term obligations37,579 37,968 
Current portion of operating lease liabilities25,845 25,909 
Total current liabilities492,031 514,392 
Long-term obligations, less current portion332,947 339,313 
Operating lease liabilities, less current portion55,642 56,111 
Deferred income tax liabilities58,032 48,051 
Other long-term obligations848 882 
Total liabilities939,500 958,749 
Equity:
Preferred stock, $0.001 par value, 5,000,000 shares authorized; none issued or outstanding
— — 
Common stock, $0.001 par value, 60,000,000 shares authorized; 38,381,255 and 38,307,521 shares issued; 32,818,871 and 32,776,148 shares outstanding
38 38 
Additional paid-in capital
825,138 818,201 
Treasury stock, at cost, 5,562,384 and 5,531,373 shares of common stock
(477,718)(474,854)
Retained earnings852,168 791,156 
Total Amedisys, Inc. stockholders’ equity1,199,626 1,134,541 
Noncontrolling interests45,448 45,424 
Total equity1,245,074 1,179,965 
Total liabilities and equity$2,184,574 $2,138,714 


4


AMEDISYS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS AND DAYS REVENUE OUTSTANDING
(Amounts in thousands, except statistical information)

For the Three-Month 
Periods Ended March 31,
20252024
Cash Flows from Operating Activities:
Net income$61,821 $14,594 
Adjustments to reconcile net income to net cash used in operating activities:
Depreciation and amortization (inclusive of depreciation included in cost of service)6,787 6,138 
Non-cash compensation6,844 7,886 
Amortization and impairment of operating lease right of use assets8,645 8,566 
(Gain) loss on disposal of property and equipment(34)
Gain on equity method investment(48,093)— 
Deferred income taxes9,981 2,594 
Equity in earnings from equity method investments(1,794)(910)
Amortization of deferred debt issuance costs248 248 
Return on equity method investments2,320 170 
Changes in operating assets and liabilities:
Patient accounts receivable(23,564)(46,806)
Other current assets3,480 (1,696)
Operating lease right of use assets(1,186)(1,042)
Other assets88 155 
Accounts payable(10,913)8,652 
Accrued expenses(10,658)3,029 
Other long-term obligations(34)(591)
Operating lease liabilities(7,625)(7,532)
Net cash used in operating activities(3,687)(6,541)
Cash Flows from Investing Activities:
Proceeds from the sale of deferred compensation plan assets27 21 
Proceeds from the sale of property and equipment15 — 
Purchases of property and equipment(1,215)(2,670)
Investments in technology assets(201)(223)
Investment in equity method investee— (196)
Net cash used in investing activities(1,374)(3,068)
Cash Flows from Financing Activities:
Proceeds from the issuance of stock upon exercise of stock options93 — 
Shares withheld to pay taxes on non-cash compensation(2,864)(617)
Noncontrolling interest contributions— 1,764 
Noncontrolling interest distributions(785)(756)
Principal payments of long-term obligations(9,744)(8,941)
Net cash used in financing activities(13,300)(8,550)
Net decrease in cash, cash equivalents and restricted cash(18,361)(18,159)
Cash, cash equivalents and restricted cash at beginning of period303,242 138,863 
Cash, cash equivalents and restricted cash at end of period$284,881 $120,704 
Supplemental Disclosures of Cash Flow Information:
Cash paid for interest$6,177 $8,188 
Cash paid for income taxes, net of refunds received$907 $828 
Cash paid for operating lease liabilities$8,811 $8,574 
Cash paid for finance lease liabilities$4,121 $2,236 
5


Supplemental Disclosures of Non-Cash Activity:
Right of use assets obtained in exchange for operating lease liabilities$7,006 $7,173 
Right of use assets obtained in exchange for finance lease liabilities$3,158 $4,326 
Reductions to right of use assets resulting from reductions to operating lease liabilities$75 $168 
Reductions to right of use assets resulting from reductions to finance lease liabilities$415 $496 
Days revenue outstanding (1)45.7 54.1 

(1) Our calculation of days revenue outstanding at March 31, 2025 and 2024 is derived by dividing our ending patient accounts receivable by our average daily patient revenue for the three-month periods ended March 31, 2025 and 2024, respectively.
6


AMEDISYS, INC. AND SUBSIDIARIES
RECONCILIATION OF NON-GAAP FINANCIAL MEASURES TO GAAP MEASURES
(Amounts in thousands, except per share data)


Adjusted Earnings Before Interest, Taxes, Depreciation and Amortization ("Adjusted EBITDA") Reconciliation:
For the Three-Month Periods
Ended March 31,
20252024
Net income attributable to Amedisys, Inc.$61,012 $14,400 
Add:
        Income tax expense29,384 12,633 
        Interest expense, net3,549 6,392 
        Depreciation and amortization6,787 6,138 
        Certain items(1)
(31,903)20,296 
Adjusted EBITDA(2)(5)
$68,829 $59,859 

Adjusted Net Income Attributable to Amedisys, Inc Reconciliation:
For the Three-Month Periods
Ended March 31,
20252024
Net income attributable to Amedisys, Inc.$61,012 $14,400 
Add:
        Certain items(1)
(19,430)19,548 
Adjusted net income attributable to Amedisys, Inc.(3)(5)
$41,582 $33,948 

Adjusted Net Income Attributable to Amedisys, Inc. per Diluted Share Reconciliation:
For the Three-Month Periods
Ended March 31,
20252024
Net income attributable to Amedisys, Inc. common stockholders per diluted share$1.84 $0.44 
Add:
        Certain items(1)
(0.59)0.59 
Adjusted net income attributable to Amedisys, Inc. common stockholders per diluted share(4)(5)
$1.25 $1.03 

7


(1)    The following details the certain items for the three-month periods ended March 31, 2025 and 2024:

Certain Items (in thousands):
For the Three-Month Periods
Ended March 31,
20252024
(Income) Expense(Income) Expense
Certain Items Impacting General and Administrative Expenses:
Merger-related expenses$16,769 $20,667 
Certain Items Impacting Total Other Income (Expense):
Other (income) expense, net (includes $48,093 gain on equity method investment)(48,672)(371)
Total$(31,903)$20,296 
Net of tax$(19,430)$19,548 
Diluted EPS$(0.59)$0.59 



(2) Adjusted EBITDA is defined as net income attributable to Amedisys, Inc. before net interest expense, provision for income taxes and depreciation and amortization, excluding certain items as described in footnote 1.
(3)    Adjusted net income attributable to Amedisys, Inc. is defined as net income attributable to Amedisys, Inc. calculated in accordance with GAAP excluding certain items as described in footnote 1.
(4)    Adjusted net income attributable to Amedisys, Inc. common stockholders per diluted share is defined as diluted income per share calculated in accordance with GAAP excluding the earnings per share effect of certain items as described in footnote 1.
(5)    Adjusted EBITDA, adjusted net income attributable to Amedisys, Inc. and adjusted net income attributable to Amedisys, Inc. common stockholders per diluted share should not be considered as an alternative to, or more meaningful than, income before income taxes or other measures calculated in accordance with GAAP. These calculations may not be comparable to a similarly titled measure reported by other companies, since not all companies calculate these non-GAAP financial measures in the same manner.
8
1 Amedisys First Quarter 2025 Earnings Release Supplemental Slides April 23, 2025 EXHBIT 99.2


 
2 This presentation may include forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based upon current expectations and assumptions about our business that are subject to a variety of risks and uncertainties that could cause actual results to differ materially from those described in this presentation. You should not rely on forward-looking statements as a prediction of future events. Additional information regarding factors that could cause actual results to differ materially from those discussed in any forward-looking statements are described in reports and registration statements we file with the SEC, including our Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, copies of which are available on the Amedisys internet website http://www.amedisys.com or by contacting the Amedisys Investor Relations department at (225) 292-2031. We disclaim any obligation to update any forward-looking statements or any changes in events, conditions or circumstances upon which any forward-looking statement may be based except as required by law. www.amedisys.com NASDAQ: AMED We encourage everyone to visit the Investors Section of our website at www.amedisys.com, where we have posted additional important information such as press releases, profiles concerning our business, clinical operations and control processes and SEC filings. FORWARD-LOOKING STATEMENTS EXHBIT 99.2


 
3 HIGHLIGHTS AND SUMMARY FINANCIAL RESULTS (ADJUSTED): 1Q’25(1) 1. The financial results for the three-month periods ended March 31, 2024 and 2025 are adjusted for certain items and should be considered a non-GAAP financial measure. A reconciliation of these non-GAAP financial measures is included in the corresponding 8-K detailing quarterly results for each respective reporting period. 2. Same Store volume – Includes admissions and recertifications. 3. Same Store is defined as care centers that we have operated for at least the last 12 months and startups that are an expansion of a same store care center. 4. Free cash flow is defined as cash flow from operations less routine capital expenditures and required debt repayments. Growth Metrics: • Total Admissions: 999 (+31%) • Number of admitting JVs: 8 Other Statistics: • Patient Satisfaction: 90% High Acuity Care Adjusted Financial Results Same Store (3): • Admissions: +3.6% • ADC: -0.1% Other Statistics: • Revenue per Day: $179.48 (+3.7%) • Cost per day: $92.14 (+2.2%) HospiceHome Health Same Store(3) : • Admissions: +7% • Volume(2): +5% Other Statistics: • Medicare Revenue per Episode: $3,008 (+0.3%) • Cost per Visit: $119.99 (+2.9%) Amedisys Consolidated • Revenue: +4% • EBITDA: +15% • EBITDA Margin: 11.6% • Net Leverage ratio: 0.3x • Revolver availability: $508.0M • CFFO: $(3.7)M • DSO: 45.7 (vs. Q4’24 of 43.0 and down 8.4 days vs prior year) Amedisys Consolidated Amedisys Consolidated Regulatory 2025 Reimbursement • Final Hospice industry rule – industry estimated impact +2.9% increase (effective 10/1/24) • Final Home Health industry rule – industry estimated impact +0.5% increase (effective 1/1/25) 2026 Reimbursement • Proposed Hospice industry rule – industry estimated impact +2.4% increase (effective 10/1/25) $ in Millions, except EPS 1Q24 1Q25 Home Health 364.0$ 379.2$ Hospice 201.0 206.2 High Acuity Care 6.4 9.4 Total Revenue 571.4$ 594.8$ Gross Margin % 44.1% 44.2% Adjusted EBITDA 59.9$ 68.8$ 10.5% 11.6% Adjusted EPS 1.03$ 1.25$ Free cash flow(4) (16.6)$ (14.6)$ EXHBIT 99.2


 
4 55.7% 17.6% 26.7% Home Health Revenue Medicare FFS Private Episodic & Case Rate Per Visit 63.8% 34.6% 1.6% Amedisys Consolidated Revenue Home Health Hospice High Acuity Care • Medicare FFS: Reimbursed for a 30-day period of care • Private Episodic: MA and Commercial plans who reimburse us for a 30-day period of care or 60-day episode of care, majority of which range from 90% - 100% of Medicare rates • Case Rate: Managed care payors who reimburse us per admission • Per Visit: Managed care, Medicaid and private payors who reimburse us per visit performed 95.5% 4.5% Hospice Revenue Medicare FFS Private Hospice Per Day Reimbursement: • Routine Care: Patient at home with symptoms controlled, ~96% of the Hospice care provided • Continuous Care: Patient at home with uncontrolled symptoms • Inpatient Care: Patient in facility with uncontrolled symptoms • Respite Care: Patient at facility with symptoms controlled • Home Health: 347 care centers; 34 states & D.C. • Hospice: 164 care centers; 31 states • High Acuity Care: 8 admitting joint ventures; 7 states; 32 referring hospitals • Total: 519 care centers/joint ventures; 38 states and D.C. OUR REVENUE SOURCES: 1Q’25 EXHBIT 99.2


 
5 HOME HEALTH AND HOSPICE SEGMENT (ADJUSTED) – 1Q’25(1) • Medicare revenue per episode up 0.3% primarily due to the 0.5% rate increase effective 1/1/2025. • Y/Y Total CPV up $3.35 (+2.9%) primarily due to raises, wage inflation and an increase in salaried clinicians and clinical managers. • EBITDA margin decreased 20 basis points. Home Health Highlights • Net revenue per day +3.7% due to the +2.9% Hospice rate update effective 10/1/2024 and the mix in days. • Cost per day up $1.98 (+2.2%) primarily due to raises. • EBITDA margin up 60 basis points primarily due to the 2025 rate increase (effective 10/1/2024) partially offset by raises. Hospice Highlights 1. The financial results for the three-month periods ended March 31, 2024 and 2025 are adjusted for certain items and should be considered a non-GAAP financial measure. A reconciliation of these non-GAAP financial measures is included in the corresponding 8-K detailing quarterly results for each respective reporting period. 2. Pre-Corporate EBITDA does not include any corporate G&A expenses. 3. Same Store information represents the percent change in volume, admissions or ADC for the period as a percent of the volume, admissions or ADC of the prior period. 4. Same Store is defined as care centers that we have operated for at least the last 12 months and startups that are an expansion of a same store care center. $ in Millions 1Q24 1Q25 Medicare 215.8$ 211.2$ Non-Medicare 148.2 168.0 Home Health Revenue $364.0 $379.2 Gross Margin % 42.6% 42.3% Pre-Corporate EBITDA(2) $63.9 $66.1 17.6% 17.4% Operating Statistics Same Store Growth(3)(4) Admissions 10% 7% Volume 8% 5% Medicare revenue per episode $2,998 $3,008 Medicare recert rate 31.7% 31.4% Total cost per visit $116.64 $119.99 HOME HEALTH $ in Millions 1Q24 1Q25 Medicare 190.0$ 196.9$ Non-Medicare 11.0 9.3 Hospice Revenue $201.0 $206.2 Gross Margin % 47.9% 48.7% Pre-Corporate EBITDA(2) $48.8 $51.3 24.3% 24.9% Operating Statistics Admit growth - same store(3)(4) -3% 4% ADC growth - same store(3)(4) 0.3% -0.1% ADC 12,767 12,759 Avg. discharge length of stay 92 94 Revenue per day (net) $173.04 $179.48 Cost per day $90.16 $92.14 HOSPICE EXHBIT 99.2


 
6 GENERAL & ADMINISTRATIVE EXPENSES – ADJUSTED (1,2) Notes: • Year over year total G&A as a percentage of revenue decreased 80 basis points • $2.8 million increase in total G&A is primarily due to planned wage increases, employee-related insurance costs and higher information technology fees partially offset by lower legal fees and incentive compensation costs. • Total G&A decreased ~$7 million sequentially primarily due to a seasonality driven decrease in health insurance costs and lower incentive compensation costs. 1. The financial results for the three-month periods ended March 31, 2024, June 30, 2024, September 30, 2024, December 31, 2024 and March 31, 2025 are adjusted for certain items and should be considered a non-GAAP financial measure. A reconciliation of these non-GAAP financial measures is included in the corresponding 8-K detailing quarterly results for each respective reporting period. 2. Adjusted G&A expenses do not include depreciation and amortization. Impacted by raises and employee-related insurance costs. 33.8% 33.1% 33.7% 33.9% 33.0% 32.0% 34.0% 36.0% 1Q24 2Q24 3Q24 4Q24 1Q25 Total G&A as a Percent of Revenue G&A as a Percent of Revenue $ in Millions 1Q24 2Q24 3Q24 4Q24 1Q25 Home Health Segment - Total 91.0$ 92.4$ 93.3$ 95.5$ 94.6$ % of HH Revenue 25.0% 24.5% 25.0% 25.3% 24.9% Hospice Segment - Total 48.0 48.7 49.7 50.6 49.8 % of HSP Revenue 23.9% 23.9% 23.9% 23.8% 24.2% High Acuity Care Segment - Total 5.9 5.4 5.7 5.7 5.0 % of HAC Revenue 92.5% 55.1% 74.2% 70.4% 53.2% Total Corporate Expenses 48.4 49.2 49.6 50.8 46.7 % of Total Revenue 8.5% 8.3% 8.4% 8.5% 7.9% Total 193.3$ 195.7$ 198.3$ 202.7$ 196.1$ % of Total Revenue 33.8% 33.1% 33.7% 33.9% 33.0% 1Q24 2Q24 3Q24 4Q24 1Q25 Salary and Benefits 27.6$ 27.4$ 29.9$ 30.3$ 27.5$ Other 16.6 17.4 15.6 16.3 15.4 Corp. G&A Subtotal 44.2 44.8 45.5 46.6 42.9 Non-cash comp 4.2 4.4 4.1 4.2 3.8 Adjusted Corporate G&A 48.4$ 49.2$ 49.6$ 50.8$ 46.7$ EXHBIT 99.2


 
7 INDUSTRY LEADING QUALITY SCORES Quality of Patient Care (QPC) Patient Satisfaction (PS) • Amedisys maintains a 4-Star average in the Jan 2025 HHC Final release with 88% of our providers (representing 88% of care centers) at 4+ Stars and 46% of our providers (representing 42% of care centers) at 4.5+ Stars. •7 Amedisys providers (representing 11 care centers) rated at 5 Stars. Notes: (1) Jan 2025 QPC Star Final performance period = Apr 2023 – Mar 2024. (2) Jan 2025 PS Final performance period = Jul 2023 – Jun 2024. (3) QPC Star and PS Results for Amedisys Legacy providers only. (4) Only currently active care centers included in care center results. Metric Apr 24 Final Jul 24 Final Oct 24 Final Jan 25 Final Quality of Patient Care 4.35 4.32 4.24 4.18 Entities at 4+ Stars 95% 93% 89% 88% Metric Apr 24 Final July 24 Final Oct 24 Final Jan 25 Final Patient Satisfaction Star 3.72 3.77 3.78 4.02 Performance Over Industry +2% +3% +3% +4% 3.00 3.50 4.00 4.50 Apr 2022 Jul 2022 Oct 2022 Jan 2023 Apr 2023 Jul 2023 Oct 2023 Jan 2024 Apr 2024 Jul 2024 Oct 2024 Jan 2025 QPC Industry Performance Amedisys QPC Industry Avg QPC Top Competitor 3.00 3.50 4.00 4.50 Apr 2022 Jul 2022 Oct 2022 Jan 2023 Apr 2023 Jul 2023 Oct 2023 Jan 2024 Apr 2024 Jul 2024 Oct 2024 Jan 2025 PS Industry Performance Amedisys PS Industry Avg PS Top Competitor EXHBIT 99.2


 
8 HOSPICE QUALITY: AMEDISYS HOSPICE CONTINUES TO MOVE TOWARDS BEST-IN-CLASS Hospice Quality Notes: Included in the above analysis are only active providers. CMS Nat is an average of all providers nationally, excluding active AMED providers. EXHBIT 99.2


 
9 DEBT AND LIQUIDITY METRICS Net leverage ~0.3x 1. Net debt defined as total debt outstanding ($371.8M) less cash and cash equivalents ($284.9M). 2. Leverage ratio (net) is defined as net debt divided by last twelve months adjusted EBITDA ($254.7M). 3. Liquidity defined as the sum of cash balance and available revolving line of credit. Outstanding Term Loan 343.8$ Outstanding Revolver - Finance Leases 28.0 Total Debt Outstanding 371.8 Less: Deferred Debt Issuance Costs (1.3) Total Debt - Balance Sheet 370.5 Total Debt Outstanding 371.8 Less Cash & Cash Equivalents (284.9) Net Debt (1) 86.9$ Leverage Ratio (net) (2) 0.3 Term Loan 450.0$ Revolver Size 550.0 Borrowing Capacity 1,000.0 Revolver Size 550.0 Outstanding Revolver - Letters of Credit (42.0) Available Revolver 508.0 Plus Cash & Cash Equivalents 284.9 Total Liquidity (3) 792.9$ As of: 3/31/25 Credit Facility Outstanding Debt As of: 3/31/25 EXHBIT 99.2


 
10 CASH FLOW STATEMENT HIGHLIGHTS (1) 1Q’25 operating cash flow impacted by the timing of the payment of accounts payable and accrued expenses and a buildup in accounts receivable which is typical in the first quarter. 1. Free cash flow defined as cash flow from operations less routine capital expenditures and required debt repayments. $ in Millions 1Q24 2Q24 3Q24 4Q24 1Q25 GAAP net income (loss) 1 4.6$ 32.6$ 1 6.5$ (25.5)$ 61 .8$ Changes in working capital (36.8) 1 .0 7 5.2 34.0 (41 .7 ) Depreciation and amortization 6.1 6.4 6.8 6.7 6.8 Non-cash compensation 7 .9 8.3 6.2 8.2 6.8 Deferred income taxes 2.6 4.0 0.8 - 1 0.0 Impairment - - - 48.4 - Other (0.9) - 0.1 (1 .5) (47 .4) Cash flow from operations (6.5) 52.3 105.6 70.3 (3.7) Capital expenditures - routine (1 .2) (0.6) (1 .1 ) (0.9) (1 .2) Required debt repay ments (8.9) (9.4) (9.3) (9.6) (9.7 ) Free cash flow (16.6)$ 42.3$ 95.2$ 59.8$ (14.6)$ EXHBIT 99.2


 
11 INCOME STATEMENT ADJUSTMENTS (1) 1. The financial results for the three-month periods ended March 31, 2024, June 30, 2024, September 30, 2024, December 31, 2024 and March 31, 2025 have been adjusted for the certain items above. A reconciliation of our non-GAAP financial measures, which include these certain items, is included in the corresponding 8-K detailing quarterly results for each respective reporting period. 2. Other (income) expense, net includes a $48.1 million gain on an equity method investment recorded during the three-month period ended March 31, 2025. 1Q’25 adjustments primarily related to costs associated with pending merger and a gain on an equity method investment. $000s Income Statement Line Item 1Q24 2Q24 3Q24 4Q24 1Q25 G&A Merger-related expenses General and Administrativ e Expenses 20,667$ 1 1 ,901$ 1 6,669$ 1 7 ,401$ 1 6,7 69$ Impairment General and Administrativ e Expenses - - - 48,391 - Other Items Other (income) expense, net (2) Other Income (Expense) (37 1 ) (335) (538) (2,1 23) (48,67 2) Impairment Net Loss Attributable to Noncontrolling Interests - - - (5,867 ) - Total 20,296$ 11,566$ 16,131$ 57,802$ (31,903)$ EPS Impact 0.59$ 0.34$ 0.49$ 1.58$ (0.59)$ EBITDA Impact 20,296$ 11,566$ 16,131$ 57,802$ (31,903)$ EXHBIT 99.2